UPClytics
ENDE
Sign inStart trial
View all cases

UPC CFI 496/2024

Sep 2, 2024·EP2493466 · NOVEL ANTITUMORAL USE OF CABAZITAXEL

Follow
Case details
Status
Case Closed (Patent revoked)
Action
Counterclaim for revocation
Category
Counterclaim for revocation
Parties
Claimants
Representatives
Respondents
Representatives
Division
Munich LD
Judges
Technology
  • Chemistry
    Pharmaceuticals
Language
English
First decided
Dec 12, 2025
EPO Opposition
How this compares
The court's record for this kind of case, counted in first-instance rulings. A figure in brackets is the number of rulings a rate rests on.
Patent revokedMedian days to first decision
All UPC37% (34/91)124
Munich LDLockedLocked
Judge Matthias ZigannLockedLocked
Judge Alima ZanaLockedLocked
Judge Tobias PichlmaierLockedLocked

At the UPC: STADA Arzneimittel AG (9 cases)·Sanofi Group (33 cases)

Start 14-day free trialAlready a user? Sign in
Related cases
All proceedings on this patent

This dispute contains 10 other proceedings

UPC CoA 22/2026·UPC CoA 25/2026·UPC CFI 106/2026·UPC CFI 108/2026·UPC CFI 146/2024 and 5 more

10 other defendants litigating the same or a related patent

UPC CoA 23/2026·UPC CoA 24/2026·UPC CoA 26/2026·UPC CoA 27/2026·UPC CFI 503/2024 and 5 more

Start a free trial to see how each one ended.

More cases: Munich LD·2024

Decisions
  • 2025-12-12
    Infringement ActionPublic

    Summary: The Munich Local Division issued a rectification order under Rule 353 RoP correcting factual errors in a prior decision in the Sanofi v. Stada/Dr Reddy/Zentiva proceedings, including corrections regarding marketing authorisation holders and expert witness attribution.

    Show the legal issues (1)
    • Rectification of decisions Rule 353 RoP
  • 2025-12-12
    Infringement ActionPublic

    Summary: The Munich Local Division found patent EP 2 493 466 (relating to cabazitaxel pharmaceutical formulations) invalid for lack of inventive step in infringement proceedings brought by Sanofi against STADA, Dr. Reddy's and Zentiva entities, dismissing the infringement claims.

    Show the legal issues (4)
    • Inventive step (cabazitaxel formulation)
    • Infringement
    • Pharmaceutical patent
    • Counterclaim for revocation
Documents
Document titleDatePublic
Receipt2026-03-31Not public
Cover sheet2026-03-31Not public
Exhibit Defendant2026-03-31Not public
Application document Defendant2026-03-31Not public
Note2026-03-11Not public
Note2026-02-06Not public
Receipt2026-02-04Not public
Cover sheet2026-02-04Not public
Application document Claimant2026-02-04Not public
Receipt2026-01-12Not public
Cover sheet2026-01-12Not public
Exhibit document Applicant2026-01-12Not public
Exhibit document Applicant2026-01-12Not public
Exhibit document Applicant2026-01-12Not public
Exhibit document Applicant2026-01-12Not public
Application document Applicant2026-01-12Not public
Case closed2025-12-16Not public
Decision2025-12-16Public
Decision2025-12-12Not public
Decision2025-12-12Not public
Other Documents2025-11-25Not public
Cover sheet2025-10-08Not public
Exhibit2025-10-08Not public
Further pleadings2025-10-08Not public
Receipt2025-10-08Not public
Cover sheet2025-10-08Not public
Further pleadings2025-10-08Not public
Exhibit2025-10-08Not public
Receipt2025-10-08Not public
oral hearing reference - IC2025-09-15Not public
oral hearing reference - IC2025-09-15Not public
Fix-Interim-Conference-Date2025-09-10Not public
Interim-Conference-Decision2025-09-10Not public
Written-Procedure-Closure2025-09-10Not public
Acknowledgement-of-lodging2025-08-09Not public
Rejoinder2025-08-09Not public
Acknowledgement-of-lodging2025-08-09Not public
Rejoinder2025-08-09Not public
Acknowledgement-of-lodging2025-08-08Not public
Rejoinder2025-08-08Not public
Acknowledgement-of-lodging2025-08-08Not public
Rejoinder2025-08-08Not public
Acknowledgement-of-lodging2025-08-08Not public
Acknowledgement-of-lodging2025-08-08Not public
Rejoinder2025-08-08Not public
Rejoinder2025-08-08Not public
Acknowledgement-of-lodging2025-08-08Not public
Rejoinder2025-08-08Not public
Acknowledgement-of-lodging2025-08-08Not public
Rejoinder2025-08-08Not public
Acknowledgement-of-lodging2025-08-08Not public
Acknowledgement-of-lodging2025-08-08Not public
Rejoinder2025-08-08Not public
Rejoinder2025-08-08Not public
Acknowledgement-of-lodging2025-08-08Not public
Rejoinder2025-08-08Not public
Acknowledgement-of-lodging2025-08-08Not public
Exhibit No. B.392025-08-08Not public
Exhibit No. B.402025-08-08Not public
Exhibit No. B.2.2.22025-08-08Not public
Exhibit No. 0.52025-08-08Not public
Exhibit No. B.302025-08-08Not public
Exhibit No. B.22.1bis2025-08-08Not public
Exhibit No. B.412025-08-08Not public
Exhibit No. B.372025-08-08Not public
Exhibit No. B.432025-08-08Not public
Exhibit No. B.362025-08-08Not public
Rejoinder2025-08-08Not public
Exhibit No. B.352025-08-08Not public
Exhibit No. B.2.2.12025-08-08Not public
Exhibit No. B.342025-08-08Not public
Exhibit No. B.382025-08-08Not public
Exhibit No. B.312025-08-08Not public
Exhibit No. B.322025-08-08Not public
Exhibit No. B.422025-08-08Not public
Exhibit No. B.332025-08-08Not public
Acknowledgement-of-change-of-a-representative2025-07-11Not public
Application-RoP293-Receipt2025-07-11Not public
Formal-checks_Notification-of-positive-outcome2025-07-11Not public
Acknowledgement-of-change-of-a-representative2025-07-11Not public
Application-RoP293-Receipt2025-07-11Not public
Formal-checks_Notification-of-positive-outcome2025-07-11Not public
Acknowledgement-of-change-of-a-representative2025-07-11Not public
Application-RoP293-Receipt2025-07-11Not public
Formal-checks_Notification-of-positive-outcome2025-07-11Not public
Acknowledgement-of-change-of-a-representative2025-07-11Not public
Application-RoP293-Receipt2025-07-11Not public
Formal-checks_Notification-of-positive-outcome2025-07-11Not public
Acknowledgement-of-change-of-a-representative2025-07-11Not public
Application-RoP293-Receipt2025-07-11Not public
Formal-checks_Notification-of-positive-outcome2025-07-11Not public
Acknowledgement-of-change-of-a-representative2025-07-11Not public
Application-RoP293-Receipt2025-07-11Not public
Formal-checks_Notification-of-positive-outcome2025-07-11Not public
Acknowledgement-of-change-of-a-representative2025-07-11Not public
Application-RoP293-Receipt2025-07-11Not public
Formal-checks_Notification-of-positive-outcome2025-07-11Not public
Acknowledgement-of-change-of-a-representative2025-07-11Not public
Application-RoP293-Receipt2025-07-11Not public
Formal-checks_Notification-of-positive-outcome2025-07-11Not public
Acknowledgement-of-change-of-a-representative2025-07-11Not public
Application-RoP293-Receipt2025-07-11Not public
Formal-checks_Notification-of-positive-outcome2025-07-11Not public
Acknowledgement-of-change-of-a-representative2025-07-11Not public
Application-RoP293-Receipt2025-07-11Not public
Formal-checks_Notification-of-positive-outcome2025-07-11Not public
Acknowledgement-of-change-of-a-representative2025-07-11Not public
Application-RoP293-Receipt2025-07-11Not public
Formal-checks_Notification-of-positive-outcome2025-07-11Not public
Acknowledgement-of-change-of-a-representative2025-07-11Not public
Application-RoP293-Receipt2025-07-11Not public
Formal-checks_Notification-of-positive-outcome2025-07-11Not public
Application-RoP2932025-07-10Not public
Application-RoP2932025-07-10Not public
Application-RoP2932025-07-10Not public
Application-RoP2932025-07-10Not public
Application-RoP2932025-07-10Not public
Application-RoP2932025-07-10Not public
Application-RoP2932025-07-10Not public
Application-RoP2932025-07-10Not public
Application-RoP2932025-07-10Not public
Application-RoP2932025-07-10Not public
Application-RoP2932025-07-10Not public
Application2025-07-10Not public
Application2025-07-10Not public
Application2025-07-10Not public
Application2025-07-10Not public
Application2025-07-10Not public
Application2025-07-10Not public
Application2025-07-10Not public
Application2025-07-10Not public
Application2025-07-10Not public
Application2025-07-10Not public
Application2025-07-10Not public
Acknowledgement-of-lodging2025-07-08Not public
2025-07-08_Rejoinder_and_Reply_signiert2025-07-08Not public
Acknowledgement-of-lodging2025-07-08Not public
2025-07-08_Rejoinder_and_Reply_signiert2025-07-08Not public
Acknowledgement-of-lodging2025-07-08Not public
2025-07-08_Rejoinder_and_Reply_signiert2025-07-08Not public
Acknowledgement-of-lodging2025-07-08Not public
2025-07-08_Rejoinder_and_Reply_signiert2025-07-08Not public
Acknowledgement-of-lodging2025-07-08Not public
2025-07-08_Rejoinder_and_Reply_signiert2025-07-08Not public
Acknowledgement-of-lodging2025-07-08Not public
2025-07-08_Rejoinder_and_Reply_signiert2025-07-08Not public
Acknowledgement-of-lodging2025-07-08Not public
2025-07-08_Rejoinder_and_Reply_signiert2025-07-08Not public
Acknowledgement-of-lodging2025-07-08Not public
2025-07-08_Rejoinder_and_Reply_signiert2025-07-08Not public
Acknowledgement-of-lodging2025-07-08Not public
2025-07-08_Rejoinder_and_Reply_signiert2025-07-08Not public
Acknowledgement-of-lodging2025-07-08Not public
2025-07-08_Rejoinder_and_Reply_signiert2025-07-08Not public
Acknowledgement-of-lodging2025-07-08Not public
2025-07-08_Rejoinder_and_Reply_signiert2025-07-08Not public
Acknowledgement-of-lodging2025-07-08Not public
2025-07-08_Rejoinder_and_Reply_signiert2025-07-08Not public
Application-RoP2932025-06-27Not public
Application2025-06-27Not public
Hearing-Dates2025-01-24Not public
scheduling IC and OH for CC2025-01-24Public
Hearing-Dates2025-01-24Not public
Outcome of the Order2025-01-17Not public
R 305 second - final2025-01-17Public
Hearing Reference2025-01-16Not public
Hearing Reference2025-01-16Not public
Hearing-Dates2025-01-13Not public
R 305 second- oral comments2025-01-13Not public
Receipt2025-01-09Not public
Application2025-01-09Not public
Exhibit No. A.02.22025-01-09Not public
Outcome of the Order2024-12-19Not public
extension request2024-12-19Public
Receipt2024-12-13Not public
Extension request2024-12-12Not public
Formal-checks_Notification-of-positive-outcome2024-11-01Not public
Acknowledgement-of-lodging2024-11-01Not public
Reply and Defence2024-11-01Not public
Formal-checks_Notification-of-positive-outcome2024-11-01Not public
Acknowledgement-of-lodging2024-11-01Not public
Reply and Defence2024-11-01Not public
Formal-checks_Notification-of-positive-outcome2024-11-01Not public
Acknowledgement-of-lodging2024-11-01Not public
Reply and Defence2024-11-01Not public
Formal-checks_Notification-of-positive-outcome2024-11-01Not public
Acknowledgement-of-lodging2024-11-01Not public
Reply and Defence2024-11-01Not public
Formal-checks_Notification-of-positive-outcome2024-11-01Not public
Acknowledgement-of-lodging2024-11-01Not public
Reply and Defence2024-11-01Not public
Formal-checks_Notification-of-positive-outcome2024-11-01Not public
Acknowledgement-of-lodging2024-11-01Not public
Reply and Defence2024-11-01Not public
Formal-checks_Notification-of-positive-outcome2024-11-01Not public
Acknowledgement-of-lodging2024-11-01Not public
Reply and Defence2024-11-01Not public
Formal-checks_Notification-of-positive-outcome2024-11-01Not public
Acknowledgement-of-lodging2024-11-01Not public
Reply and Defence2024-11-01Not public
Formal-checks_Notification-of-positive-outcome2024-11-01Not public
Acknowledgement-of-lodging2024-11-01Not public
Reply and Defence2024-11-01Not public
Formal-checks_Notification-of-positive-outcome2024-11-01Not public
Acknowledgement-of-lodging2024-11-01Not public
Reply and Defence2024-11-01Not public
Formal-checks_Notification-of-positive-outcome2024-11-01Not public
Acknowledgement-of-lodging2024-11-01Not public
Reply and Defence2024-11-01Not public
Formal-checks_Notification-of-positive-outcome2024-11-01Not public
Acknowledgement-of-lodging2024-11-01Not public
Reply and Defence2024-11-01Not public
epoUploadDocumentsWorkflow2024-09-17Not public
Document from EPO2024-09-16Not public
Notification Of Service2024-09-16Not public
Zustellbestätigung - E-Mail2024-09-16Not public
Notification Of Service2024-09-16Not public
Zustellbestätigung - E-Mail2024-09-16Not public
Letter for Service2024-09-16Not public
Notification Of Service2024-09-16Not public
Zustellbestätigung - E-Mail2024-09-16Not public
Notification Of Service2024-09-16Not public
Zustellbestätigung - E-Mail2024-09-16Not public
Notification Of Service2024-09-16Not public
Zustellbestätigung - E-Mail2024-09-16Not public
Notification Of Service2024-09-16Not public
Zustellbestätigung - E-Mail2024-09-16Not public
Notification Of Service2024-09-16Not public
Zustellbestätigung - E-Mail2024-09-16Not public
Acknowledgement of access to case2024-09-13Not public
Acknowledgement of access to case2024-09-13Not public
Acknowledgement of access to case2024-09-13Not public
Acknowledgement of access to case2024-09-13Not public
Acknowledgement of access to case2024-09-13Not public
Acknowledgement of access to case2024-09-13Not public
Letter for Service2024-09-13Not public
Letter for Service2024-09-13Not public
Letter for Service2024-09-13Not public
Letter for Service2024-09-13Not public
Letter for Service2024-09-13Not public
Letter for Service2024-09-13Not public
Panel-Appointment2024-09-11Not public
EPO-Request-for-case-pending2024-09-11Not public
Acknowledgement-of-lodging2024-09-11Not public
Formal-checks_Notification-of-positive-outcome2024-09-11Not public
Decision T 0096/20 of the EPO Boards of Appeal dated 22 April 20212024-09-02Not public
Tannock, et al., J. Clin. Oncol. 1996, 14(6), 1756-64.2024-09-02Not public
de Bono et al. article (cf. D15) as published on October 2, 20102024-09-02Not public
Winquist et al., The Canadian Journal of Urology, 15(1), February 20082024-09-02Not public
Decision T 0239/16, dated 13 September 20072024-09-02Not public
WO 96/30355 A1 published 3 October 19962024-09-02Not public
“Un projet de medicament stoppé in extremis”, Les Echos, 22 Dec 20092024-09-02Not public
Attard et al, Pathologie Biologie 54 (2006) 72-842024-09-02Not public
Fossà, et al., J. Clin. Oncol. 2001, 19(1), 62-71.2024-09-02Not public
ICH Harmonised Tripartite Guideline “General Considerations for Clinical Trials E8” dated 17 July 19972024-09-02Not public
US 61/256160, first priority document2024-09-02Not public
Declaration by Prof. Dr Kurt Miller dated 12 May 20212024-09-02Not public
Blog post by Dr Barry Mirtsching on “the Prostate Cancer blog”, dated 12 October 20072024-09-02Not public
Expert Opinion Dr. Kai Gevers dated 26 March 20212024-09-02Not public
FDA prescribing information of JEVTANA (cabazitaxel); revised in June 20102024-09-02Not public
FDA label for Taxotere (2007)2024-09-02Not public
EMA “ICH Topic E 8 General Considerations for Clinical Trials”, published March 1998.2024-09-02Not public
Extract relating to trial no. NCT00417079 dated 11 September 20092024-09-02Not public
Tribunal Judiciaire de Paris, Ordonnance de référé, 17 June 2021, N° RG 21/53849 – N° Portalis 352J-W-B7F-CUJG22024-09-02Not public
WO 2011/051894, original application2024-09-02Not public
Sartor et al., Urology 52 (2), 1998, 252-2562024-09-02Not public
Goetz et al., Clinical Pharmacology, Proceedings of ASCO Volume 20 20012024-09-02Not public
Document “Information for the patient concerning the clinical study 42446 02041”, cited as “document 55” in EPO Boards o2024-09-02Not public
“Un projet de medicament stoppé in extremis”, Les Echos, 22 Dec 20092024-09-02Not public
Reuters newsclip confirming the date of D23 (AE14)2024-09-02Not public
Shigeta et al., Correspondence, The Lancet, 377, 2011, 121-1222024-09-02Not public
Expert Opinion Dr. Kai Gevers dated 26 March 20212024-09-02Not public
Document “Zeltia Junta General de Accionistas 2003”, cited as “document D2”in EPO Boards of Appeal decision T 2506/122024-09-02Not public
Sternberg et al. Oncology 2013;85: 208-2152024-09-02Not public
Summary of product characteristics of Taxotere; revision of November 20082024-09-02Not public
October 2008 version of the Helsinki Declaration2024-09-02Not public
Mita et al., Clin Cancer Res 2009; 15(2) published 15 January 20092024-09-02Not public
Declaration by Dr Oliver Sartor dated 23 June 2016 filed in Case IPR2016-00712, Patent US 8,927,5922024-09-02Not public
Albarqouni, “Tutorial about Hazard Ratios – Students 4 Best Evidence”, https://s4be.cochrane.org/blog/2016/04/05/tutoria2024-09-02Not public
Galletti et al., ChemMedChem 2007, 2, 920-9422024-09-02Not public
Jaehde, Lehrbuch der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-2024-09-02Not public
Curriculum Vitae of Prof. Dr. Kurt Miller2024-09-02Not public
Decision of the EPO Boards of Appeal T1806/18 dated 21 October 20212024-09-02Not public
Pivot et al., Annals of Oncology, 19, 2008, 1547-15522024-09-02Not public
Guidance document entitled “Cabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer – second line afte2024-09-02Not public
Declaration by Dr. Alton Oliver Sartor, M.D., December 23, 20202024-09-02Not public
Sanofi-aventis Press Release, 21 December 20092024-09-02Not public
Rosenberg et al., Cancer 2007, 110(3), 556-5632024-09-02Not public
Summary of product characteristics of Jevtana®, Sanofi Genzyme, April 20172024-09-02Not public
Bissery et al., Pharmacology and experimental therapeutics, Proceedings of the American Association for Cancer Research,2024-09-02Not public
Blog posts by Dr Barry Mirtsching on the “Center for Oncology Research & Treatment-Dallas, TX Innovative Cancer Treatmen2024-09-02Not public
Aller et al. Proceedings of the American Association for Cancer Research 2000, 41: 302, Abstract #19232024-09-02Not public
Summary of product characteristics of Jevtana®, Sanofi Genzyme, April 20172024-09-02Not public
Beardsley et al., Curr. Op. Support. Palliat. Care 2008, 2(3), 161-1662024-09-02Not public
Gaisky et al., Nature Reviews, Drug Discovery, 9, 2010, 6772024-09-02Not public
Sanchez et al. Prostate 2009 (15 September) 69: 1448- 14592024-09-02Not public
EMA Guideline on the Evaluation of Anticancer Medicinal products in Man, 20062024-09-02Not public
Sanofi-Aventis Annual Review, 17 April 20092024-09-02Not public
Sartor, Endpoints in prostate cancer clinical trials. Urology 2002, 60, 101-1082024-09-02Not public
T 3165/19 of the EPO Boards of Appeal dated 9 January 20232024-09-02Not public
WO 2005/028462, published 31 March 20052024-09-02Not public
Counterclaim for revocation2024-09-02Not public
Figg et al., Cancer Biology & Therapy, 10, 2010, 1233-12342024-09-02Not public
Declaration by Dr Samuel Denmeade dated 30 April 20212024-09-02Not public
Pal et al., Clinical Interventions in Aging, 5, 2010, 395-4022024-09-02Not public
Sanofi Press Release, “A promising R&D portfolio, well positioned to deliver future growth”, September 17, 2007.2024-09-02Not public
Protocol of clinical trial NCT00417079 (“XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Ref2024-09-02Not public
USPTO Decision dated 21 September 2017, Case IPR2016-00712, Patent US 8,927,5922024-09-02Not public
Berthold et al., Ann. Oncol., 19, 2008, 1749-17532024-09-02Not public
Patentee’s response dated 4 January 2021 to the Summons to oral proceedings in examination proc.2024-09-02Not public
Sava, et al., Expert Rev. Anticancer Ther. 2005, 5(1), 53-62.2024-09-02Not public
Leaflet “XRP6258 and XRP9881 Novel Taxoids” by Aventis Pharmaceuticals Inc., 20032024-09-02Not public
Blog posts by Dr Barry Mirtsching on the “Center for Oncology Research & Treatment-Dallas, TX Innovative Cancer Treatmen2024-09-02Not public
Fundamental statistics – Educational slide module, date of preparation: February 2023, Across T2D – Academy for cardiova2024-09-02Not public
US 2005/0065138 A1, published 24 March 20052024-09-02Not public
Tannock et al., J. Clin. Oncol. 1989, 7(5), 590-7.2024-09-02Not public
de Bono et al., Lancet, 376, 2010, 1147-11542024-09-02Not public
Decision T 2506/12 of the EPO Boards of Appeal dated 4 October 20162024-09-02Not public
Jaehde, Lehrbuch der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-2024-09-02Not public
Tribunal Judiciaire de Paris, Ordonnance de référé, 17 June 2021, N° RG 21/53849 – N° Portalis 352J-W-B7F-CUJG22024-09-02Not public
MPEP Section 6012024-09-02Not public
Assignment before the USPTO2024-09-02Not public
Tannock et al., N Engl J Med 2004, 351(15), 1502-15122024-09-02Not public
EMA Assessment Report for Jevtana (cabazitaxel), 20 January 20112024-09-02Not public
List of documents from the EPO opposition proceedings (includes further documents on which this statement of defence and2024-09-02Not public
T 2963/19 of the EPO Boards of Appeal dated 18 March 20222024-09-02Not public
Oh et al., Urology, 2006, 67:1235-1240.2024-09-02Not public
Expert declaration by Prof. Muller including Annexes 1 to 5 cited therein2024-09-02Not public